Pharma: Trends and Uses Of Mobile Apps and Digital Marketing
34.9K views | +10 today
Follow
 
Rescooped by eMedToday from mHealth- Advances, Knowledge and Patient Engagement
onto Pharma: Trends and Uses Of Mobile Apps and Digital Marketing
Scoop.it!

'The web is dead - and the app killed it'

'The web is dead - and the app killed it' | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Combined with apps, the newer, nimbler mobile net is making the internet a far more useful place

Via Alex Butler, eMedToday
eMedToday's insight:

Pharma need to think apps. Here is why and why e detailing needs to be done on an mobile app.

more...
eMedToday's curator insight, September 2, 2013 7:06 AM

One reason we're using apps instead of the web is that we are mobile. The other reason is even more important: we're suffering from information overload. Despite all the talk of " big data", too much of it is hard to digest. The brain evolved in a world of limited information; abundance causes havoc. There is simply too much on the internet and, although the web excels at finding information, it does a poor job of filtering it.


 

Pharma: Trends and Uses Of Mobile Apps and Digital Marketing
Keep current on Pharma uses of mobile apps
Curated by eMedToday
Your new post is loading...
Your new post is loading...
Rescooped by eMedToday from PATIENT EMPOWERMENT & E-PATIENT
Scoop.it!

Pharma Marketing Blog: FDA's Dependence on User Fees & "Institutional Corruption" Blamed for Dramatic Increase in Drug Adverse Events and Deaths

Pharma Marketing Blog: FDA's Dependence on User Fees & "Institutional Corruption" Blamed for Dramatic Increase in Drug Adverse Events and Deaths | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it

An estimated 128,000 hospitalized patients die each year from Adverse Drug Reactions (ADRs. aka Adverse Events, AEs), which matches stroke as the 4th leading cause of hospital deaths (see here).

 

Deaths and serious reactions outside of hospitals would signicantly increase the totals. This does not include deaths and hospitalizations from over-dosing, errors, or recreational drug use. We know this because of  hundreds of thousands of drug "Adverse Event Reports" (AERs) received by the FDA every year directly from healthcare professionals (HCPs such as physicians, pharmacists, nurses and others), consumers (such as patients, family members, lawyers and others), and drug companies, which are normally required to send AERs it receives from HCPs to the FDA.

The chart above shows the trend in AERs received by the FDA from 2004 through 2015.


I have analyzed data from 2003 through 2014 to look at the number of AERs submitted by HCPs versus consumers, the number of serious adverse events versus the number of adverse events involving death, and the correlation between serious AEs and user fees paid to the FDA by drug companies. I see some interesting trends in the data.

 

More...


Via Pharma Guy, Lionel Reichardt / le Pharmageek
more...
Pharma Guy's curator insight, July 26, 6:30 AM

What's responsible for the sharp rise in AERs submitted to FDA by consumers? Could it be class action lawsuits and attorney commercials about the deadly side effects of drugs? Read “AMA Chastises Lawyers for Alarming Drug Ads”; http://sco.lt/5RkA4X

Scooped by eMedToday
Scoop.it!

The Best in B2C Pharmaceutical and Health Care Content Marketing 

Pharmaceutical and healthcare companies have a huge opportunity to be the go-to-source of information people around the world are searching for.
more...
No comment yet.
Scooped by eMedToday
Scoop.it!

Global Big Pharma Licensing Trends 2011-15 - Research and Markets | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing

Global Big Pharma Licensing Trends 2011-15 - Research and Markets | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Research and Markets has announced the addition of the "Big Pharma Licensing Trends, 2011-15" report to their offering.
more...
No comment yet.
Scooped by eMedToday
Scoop.it!

Apple secures ResearchKit partnership with GlaxoSmithKline

Apple secures ResearchKit partnership with GlaxoSmithKline | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Apple has established its first industry partnership for its clinical platform, ResearchKit, teaming up with pharmaceutical giant GlaxoSmithKline.
more...
No comment yet.
Scooped by eMedToday
Scoop.it!

Digital Health Tools Find A Willing Consumer Audience

Doctors - at least in Europe - have concerns about the potential for consumers to misinterpret digital health data and for digital health tools to fuel hypochondria.
more...
No comment yet.
Rescooped by eMedToday from Pharma & Medical Devices
Scoop.it!

Drugmakers’ Pricing Power Remains Strong

Drugmakers’ Pricing Power Remains Strong | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Drug companies’ power to raise prices is firmly intact despite pushback from health insurers and scrutiny by U.S. lawmakers. More than two-thirds of the 20 largest​​pharmaceutical companies said price increases​boosted sales of some or most of their biggest ​products in the first quarter.

Via Richard Meyer
more...
No comment yet.
Scooped by eMedToday
Scoop.it!

Mobile app allows GlaxoSmithKline to track patients in real-time arthritis study

Mobile app allows GlaxoSmithKline to track patients in real-time arthritis study | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
GlaxoSmithKline has become the first pharmaceuticals company to use a medical research app from Apple to study how disease affects patients in real time.
more...
No comment yet.
Rescooped by eMedToday from PHARMA NEWS, MULTICHANNEL & CROSSCHANNEL MAKETING
Scoop.it!

Pharma Can't Just Launch Virtual Clinical Trials and Expect Patients to Show Up

Pharma Can't Just Launch Virtual Clinical Trials and Expect Patients to Show Up | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it

Pfizer made a big splash back in 2011 with its announcement of the first “virtual” clinical trial. This news was significant because, for the first time, patients would have the opportunity to be screened, enroll, and ultimately participate in a trial entirely via internet-connected devices — in other words, without setting foot on a clinical trial site. In an expensive industry where increased efficiency and patient convenience correlate with profits, this attracted significant (if somewhat skeptical) attention.

 

Some of that skepticism was warranted. According to Michal Orri, Senior Director of Clinical Sciences at Pfizer, the trial initially failed to recruit enough patients. Was this virtual, patient-centered approach a failed model? Hardly: despite the imperfect outcome of this first trial, the Pfizer study has ignited intense interest in virtualization. Today, virtual trials are increasingly common and may, in fact, revolutionize the Pharma industry.

 

Pfizer believes that their initial trial was unsuccessful, incidentally, because it didn’t cater enough to patients. As Outsourcing-Pharma notes, their online process was overly complicated and confusing from the outset. However, after simplifying online enrollment and adding a patient-oriented call center, the trial made appreciable enrollment gains. In fact, the FDA has since requested that they validate their final procedures for more widespread adoption.

 

The essential advantage of virtual trials is that they enable patients to enroll on their own terms; mobile health, e-platforms, remote monitoring devices, wearable technology, and telemedicine all make it simpler, and more inviting, for patients to consent to and participate in trials.

 

Clinical sponsors and CROs will have to employ digital strategies with a measured approach, ensuring that these strategies meet rigorous thresholds for cost-efficiency and usefulness. Even so, most clinical researchers are cautiously optimistic, because such tech tends to allay the skepticism of the most important group of all — the patients.


Via Pharma Guy, Lionel Reichardt / le Pharmageek
more...
Pharma Guy's curator insight, July 18, 12:45 PM

Even among clinical cancer studies, as many as 50% of trials never enroll a single patient, according to a 2009 study. But it’s often an issue of education; roughly 85% of cancer patients aren’t aware that clinical treatment is even an option, says the NCBI.

 

Craig Lipset, Head of Clinical Innovation at Pfizer, explained it this way (see here): "I think some of the staunch advocates for using online and social media for recruitment are still reticent to claim silver bullet status and not use conventional channels in parallel. In terms of health literacy, the patient population is largely unaware of clinical trials and participation. You’re going in at a level where there’s still a lot of basic learning needed for individuals to make informed decisions about whether to participate. And doing that without an interaction with a healthcare provider is a challenge."

Rescooped by eMedToday from Pharma Hub
Scoop.it!

GlaxoSmithKline targets arthritis in first ResearchKit study by a drug company

GlaxoSmithKline targets arthritis in first ResearchKit study by a drug company | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Apple's ResearchKit was quickly adopted by clinical studies at a series of universities and hospitals, but a new iOS app focused on rheumatoid arthritis from pharmaceutical firm GlaxoSmithKline marks the first time a drug company has made use of the framework.
Via Philippe Marchal
more...
No comment yet.
Rescooped by eMedToday from #eHealthPromotion, #web2salute
Scoop.it!

Apple Scores GlaxoSmithKline Study in Key Test of Health Apps

Apple Scores GlaxoSmithKline Study in Key Test of Health Apps | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it

GlaxoSmithKline Plc has started a rheumatoid arthritis study using Apple Inc.’s ResearchKit, marking the first time a drugmaker has used the health system for the iPhone to conduct clinical research.

Glaxo wants to record the mobility of 300 participants over three months and will also ask the patients to input both physical and emotional symptoms, such as pain and mood. The app Glaxo created from ResearchKit comes with a guided wrist exercise that uses the phone’s sensors to record motion, giving the drugmaker a standardized measurement across all users. The company will use the results to help design better clinical trials.

The success of the study could help determine the pharmaceutical industry’s future appetite for using Apple’s products to conduct research. Drugmakers have to balance the lower costs of using the app with their ability to gather accurate, reliable data. Risks include that test subjects will tire of entering information into the app, and, given the iPhone’s $399 starting price, the sample may be skewed toward wealthier demographics.

 


Via Giuseppe Fattori
more...
No comment yet.
Rescooped by eMedToday from Pharma Hub
Scoop.it!

The Health System Pharmacist and TeleHealth Strategies

The Health System Pharmacist and TeleHealth Strategies | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
The Pharmacy Podcast Show serves pharmacy businesses, including independent retail, long-term care, specialty, and small chains. During this interview, Dr. Jeff Kosowsky, Senior Vice President of Corporate Development of American Well, a telehealth company, discusses telehealth-like technologies in the pharmacy industry and health system pharmacies, including consultations and medication therapy management. The entire interview is presented here.
Via Philippe Marchal
more...
No comment yet.
Scooped by eMedToday
Scoop.it!

Using Digital Technologies to Solve Pharma's Cost of Care Crisis | e-Santé Marketing Santé innovant

Using Digital Technologies to Solve Pharma's Cost of Care Crisis | e-Santé Marketing Santé innovant | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
The cost of care is skyrocketing. Could big data, the internet of things (IoT), and internet-based technologies be the cure?
more...
No comment yet.
Rescooped by eMedToday from Pharma & Medical Devices
Scoop.it!

Is social media still relevant in healthcare?

Is social media still relevant in healthcare? | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
KEY TAKEAWAY: While social media marketing is declining for most products and brands there are still opportunities for DTC marketers if they can overcome legal/regulatory hurdles and think outside …

Via Richard Meyer
more...
No comment yet.
Rescooped by eMedToday from PHARMA NEWS, MULTICHANNEL & CROSSCHANNEL MAKETING
Scoop.it!

Five Ways Pharma Can Benefit From Digital Health Technologies

Five Ways Pharma Can Benefit From Digital Health Technologies | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Healthcare has been understandably late to the widespread adoption of digital technology. Extremely restrictive regulations, the presence of multiple key stakeholders, a slow-to-adopt culture and other challenges distinguish healthcare from the retail and finance sectors, which have flourished with their implementations of digital technologies. But pharmaceutical companies (pharma) inhabit a unique position, situated between patients, prescribers and payers, allowing them to gain maximum benefits from a wide array of digital offerings.
Via Alex Butler, Rémy TESTON, Philippe Marchal, Lionel Reichardt / le Pharmageek
more...
No comment yet.
Scooped by eMedToday
Scoop.it!

Drugmakers’ Pricing Power Remains Strong | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing

Drugmakers’ Pricing Power Remains Strong | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Drug companies’ power to raise prices is firmly intact despite pushback from health insurers and scrutiny by U.S. lawmakers.
more...
No comment yet.
Rescooped by eMedToday from Pharma Hub
Scoop.it!

Study: Wearable data can help identify candidates for advanced Parkinson's therapies

Study: Wearable data can help identify candidates for advanced Parkinson's therapies | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Valley View, Ohio-based Great Lakes NeuroTechnologies (GLNT) which uses tablets and wearable sensors for Parkinson’s diagnosis and therapy, has published a new study looking at how wearable technology can lead to increased referral rates for therapies in Parkinson’s disease.
Via Philippe Marchal
more...
No comment yet.
Scooped by eMedToday
Scoop.it!

Global Big Pharma Licensing Trends 2011-15 - Research and Markets

Global Big Pharma Licensing Trends 2011-15 - Research and Markets | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Research and Markets has announced the addition of the "Big Pharma Licensing Trends, 2011-15" report to their offering. Key to predicting fu
more...
No comment yet.
Scooped by eMedToday
Scoop.it!

Digital Health Tools Find A Willing Consumer Audience

Doctors - at least in Europe - have concerns about the potential for consumers to misinterpret digital health data and for digital health tools to fuel hypochondria.
more...
No comment yet.
Rescooped by eMedToday from Pharma Marketing
Scoop.it!

How creating personas improves the pharma customer journey

How creating personas improves the pharma customer journey | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
An effective pharma customer journey depends on developing sound customer personas to target directly.

Via COUCH Medcomms
more...
No comment yet.
Scooped by eMedToday
Scoop.it!

New report reveals prescription medication costs may increase up to 13% in 2016

New report reveals prescription medication costs may increase up to 13% in 2016 | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Prescription medication costs are expected to rise at least 11 percent, and possibly up to 13 percent, in 2016, according to a new report on national trends and projections in prescription drug expenditures.
more...
No comment yet.
Scooped by eMedToday
Scoop.it!

Medical devices vs pharmaceuticals – a brief guide to the differences

Medical devices vs pharmaceuticals – a brief guide to the differences | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Candidates considering a move out of pharmaceuticals and into the medical devices industry should be clear on the following distinctions.
more...
No comment yet.
Rescooped by eMedToday from Pharma & Medical Devices
Scoop.it!

Why you need a better online strategy for black box products - Pharmaphorum

Why you need a better online strategy for black box products - Pharmaphorum | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Black box warnings need not impede sales if products are supported by carefully-researched online marketing strategies.

Via Richard Meyer
more...
No comment yet.
Rescooped by eMedToday from Pharma & Medical Devices
Scoop.it!

Obama blames high drug prices on firms' tunnel vision on profits

Obama blames high drug prices on firms' tunnel vision on profits | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Obama chastised drug makers for their stance on pharmaceutical pricing and challenged the companies to renew their commitment to improving public health.

Via Richard Meyer
more...
No comment yet.
Rescooped by eMedToday from Pharma & Medical Devices
Scoop.it!

Does Pharma Have A Problem With 'Ask Your Doctor ...'?

Does Pharma Have A Problem With 'Ask Your Doctor ...'? | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Does Pharma Have A Problem With 'Ask Your Doctor ...'? - 07/15/2016

Via Richard Meyer
more...
No comment yet.
Rescooped by eMedToday from #eHealthPromotion, #web2salute
Scoop.it!

Pharma’s digital health ambitions: Where are the opportunities and what’s hindering progress?

Pharma’s digital health ambitions: Where are the opportunities and what’s hindering progress? | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it

A panel discussion on the future of digital health in pharma at the MedCity CONVERGE conference in Philadelphia this week highlighted how Pfizer, Eli Lilly and Roche are using telemedicine, mobile health and connected devices as part of their drug development strategy. They also called attention to the impact of compliance on implementing these technologies.

Dennis Hancock, vice president of global connected solutions with Pfizer, noted that it built 140 clinician and patient-facing apps last year. He said the big pharma’s digital strategy revolves around three things. He emphasized that any digital health tools it enlists needs to be useful and fill an important gap. It also needs to be something that is easily used and engages with patients and it needs to be connected.


Via Giuseppe Fattori
more...
No comment yet.